BR112022008097A2 - Formulação de anticorpo que contém crizanlizumabe - Google Patents
Formulação de anticorpo que contém crizanlizumabeInfo
- Publication number
- BR112022008097A2 BR112022008097A2 BR112022008097A BR112022008097A BR112022008097A2 BR 112022008097 A2 BR112022008097 A2 BR 112022008097A2 BR 112022008097 A BR112022008097 A BR 112022008097A BR 112022008097 A BR112022008097 A BR 112022008097A BR 112022008097 A2 BR112022008097 A2 BR 112022008097A2
- Authority
- BR
- Brazil
- Prior art keywords
- crizanlizumab
- formulation containing
- antibody formulation
- antibody
- seg101
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962927720P | 2019-10-30 | 2019-10-30 | |
| US201962927716P | 2019-10-30 | 2019-10-30 | |
| US201962933692P | 2019-11-11 | 2019-11-11 | |
| US201962936269P | 2019-11-15 | 2019-11-15 | |
| PCT/US2020/057868 WO2021087050A1 (en) | 2019-10-30 | 2020-10-29 | Crizanlizumab containing antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022008097A2 true BR112022008097A2 (pt) | 2022-08-02 |
Family
ID=73544317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022008097A BR112022008097A2 (pt) | 2019-10-30 | 2020-10-29 | Formulação de anticorpo que contém crizanlizumabe |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220378912A1 (enExample) |
| EP (1) | EP4051236A1 (enExample) |
| JP (1) | JP2023501155A (enExample) |
| KR (1) | KR20220092917A (enExample) |
| CN (1) | CN114828826A (enExample) |
| AU (1) | AU2020373017B2 (enExample) |
| BR (1) | BR112022008097A2 (enExample) |
| CA (1) | CA3158921A1 (enExample) |
| CL (1) | CL2022001085A1 (enExample) |
| CO (1) | CO2022005207A2 (enExample) |
| EC (1) | ECSP22033601A (enExample) |
| IL (1) | IL292403A (enExample) |
| JO (1) | JOP20220097A1 (enExample) |
| MX (1) | MX2022005044A (enExample) |
| MY (1) | MY209141A (enExample) |
| PE (1) | PE20221276A1 (enExample) |
| PH (1) | PH12022551041A1 (enExample) |
| TW (1) | TWI893018B (enExample) |
| WO (1) | WO2021087050A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041957T2 (hu) | 2006-12-01 | 2019-06-28 | Novartis Ag | Anti-P-szelektin antitestek és eljárások azok alkalmazására gyulladásos betegségek kezelésére |
| JOP20190101A1 (ar) * | 2016-11-03 | 2019-05-05 | Novartis Ag | أنظمة علاج |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CA3092931A1 (en) * | 2018-03-08 | 2019-09-12 | Novartis Ag | Use of an anti-p-selectin antibody |
-
2020
- 2020-10-29 TW TW109137726A patent/TWI893018B/zh active
- 2020-10-29 BR BR112022008097A patent/BR112022008097A2/pt unknown
- 2020-10-29 MY MYPI2022002262A patent/MY209141A/en unknown
- 2020-10-29 PH PH1/2022/551041A patent/PH12022551041A1/en unknown
- 2020-10-29 IL IL292403A patent/IL292403A/en unknown
- 2020-10-29 MX MX2022005044A patent/MX2022005044A/es unknown
- 2020-10-29 CA CA3158921A patent/CA3158921A1/en active Pending
- 2020-10-29 EP EP20811836.4A patent/EP4051236A1/en active Pending
- 2020-10-29 PE PE2022000689A patent/PE20221276A1/es unknown
- 2020-10-29 AU AU2020373017A patent/AU2020373017B2/en active Active
- 2020-10-29 US US17/771,353 patent/US20220378912A1/en active Pending
- 2020-10-29 WO PCT/US2020/057868 patent/WO2021087050A1/en not_active Ceased
- 2020-10-29 JP JP2022524914A patent/JP2023501155A/ja active Pending
- 2020-10-29 KR KR1020227017799A patent/KR20220092917A/ko active Pending
- 2020-10-29 CN CN202080075626.2A patent/CN114828826A/zh active Pending
-
2022
- 2022-04-26 CO CONC2022/0005207A patent/CO2022005207A2/es unknown
- 2022-04-27 JO JOP/2022/0097A patent/JOP20220097A1/ar unknown
- 2022-04-27 EC ECSENADI202233601A patent/ECSP22033601A/es unknown
- 2022-04-28 CL CL2022001085A patent/CL2022001085A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL292403A (en) | 2022-06-01 |
| TW202128221A (zh) | 2021-08-01 |
| WO2021087050A1 (en) | 2021-05-06 |
| CN114828826A (zh) | 2022-07-29 |
| MX2022005044A (es) | 2022-05-16 |
| ECSP22033601A (es) | 2022-05-31 |
| CA3158921A1 (en) | 2021-05-06 |
| AU2020373017B2 (en) | 2024-06-06 |
| PH12022551041A1 (en) | 2023-04-24 |
| CO2022005207A2 (es) | 2022-05-10 |
| KR20220092917A (ko) | 2022-07-04 |
| JOP20220097A1 (ar) | 2023-01-30 |
| EP4051236A1 (en) | 2022-09-07 |
| JP2023501155A (ja) | 2023-01-18 |
| US20220378912A1 (en) | 2022-12-01 |
| CL2022001085A1 (es) | 2023-02-03 |
| AU2020373017A1 (en) | 2022-05-19 |
| MY209141A (en) | 2025-06-24 |
| TWI893018B (zh) | 2025-08-11 |
| PE20221276A1 (es) | 2022-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38425A (es) | Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
| BR112022013204A2 (pt) | Usos de uma composição e de uma preparação combinada | |
| EP3791869A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES WITH COX2 ACETYLATING AGENT AS THE ACTIVE SUBSTANCE | |
| BR112023001283A2 (pt) | Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica | |
| BR112022008457A2 (pt) | Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia | |
| CL2020002519A1 (es) | Composiciones de erenumab y usos de las mismas | |
| BR112015017903A2 (pt) | vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios | |
| BR112021026499A2 (pt) | Formulação gastrorretentiva de liberação prolongada contra helicobacter pylori | |
| BR112023017713A2 (pt) | Composições compreendendo profármacos cliváveis por enzima e nafamostato de liberação controlada e métodos de uso dos mesmos | |
| BR112022010340A2 (pt) | Composições farmacêuticas | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca | |
| BR112019001082A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de uso | |
| BR112022008097A2 (pt) | Formulação de anticorpo que contém crizanlizumabe | |
| MX2022002787A (es) | Composiciones liquidas que comprenden un conjugado de aminoacidos de levodopa y usos de estas. | |
| EP4249057A3 (en) | Betulin-containing birch bark extracts and their formulation | |
| BR112022026482A2 (pt) | Formulação altamente concentrada de proteínas de ligação ao antígeno do fator xii | |
| BR112018015031A2 (pt) | formulação de cuidados pessoais, recipiente que contém uma formulação para cuidados pessoais, e método de umedecimento da pele ou dos cabelos em pacientes | |
| BR112022008357A2 (pt) | Composições e métodos para a distribuição de canabinoides à pele | |
| BR112018007870A2 (pt) | composição imunogênica, método para a preparação de uma composição imunogênica, composição farmacêutica, vacina, método para estimular uma resposta imune em um paciente | |
| BR112017008517A2 (pt) | "composições cosméticas, utilização da composição e método para o aprimoramento de, pelo menos, uma propriedade selecionada a partir de capacidade de manuseio duradoura, controle do volume e brilho dos cabelos" | |
| BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
| JOP20220313A1 (ar) | تركيبة دوائية مائية من الليفيليماب وإستخدامها | |
| BR112022015829A2 (pt) | Composições de palmitato de vitamina a, processos para sua preparação, usos e métodos que as compreendem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |